Broken String Biosciences works on enhancing the safety and efficacy of gene editing therapies to enable transformative therapeutics for patients.

Broken String Biosciences

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.

Illumina Accelerator

The INDUCE-seq™ platform is a game changing #technology for the development of advanced #therapies that are safer by design, but what is it?
 
Watch this video to learn how the platform precisely characterizes and maps DNA double-strand breaks using Next Generation Sequencing.

Leveraging a novel PCR-free approach, the platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to unlock new therapeutic targets within the genome and to advance gene editing programs. 🧪

#CellTherapy #GeneTherapy

Our Chief Commercial Officer, Steve Becker, will be attending the CRISPR Analytical Development Summit 2024 in Boston, MA, from September 17-19 2024! 

As CRISPR technology continues to revolutionize the field of genomics, this summit is a crucial gathering of industry experts focused on the analytical development challenges and innovations driving this transformative science. Steve is eager to connect with fellow leaders, explore collaborative opportunities, and discuss how Broken String Biosciences is advancing safer, more effective genome editing solutions.

If you’re attending the summit, feel free to reach out to Steve Becker to schedule a conversation. See you there! 

#CRISPR #Genomics #GenomeEditing #Biotech #LifeSciences #Innovation #BrokenStringBiosciences

We are pleased to be sponsoring the CRISPR Analytical Development Summit 2024 in Boston, MA, from September 17-19! 🧬 This is a key event for anyone involved in CRISPR technology and its groundbreaking applications. Don't miss out on the latest insights, networking opportunities, and innovations in the field. 

Click here to learn more and secure your spot: https://lnkd.in/ev2c5swD

Let's advance the future of gene editing together!  #CRISPR #GeneEditing #Biotech #CRISPRSummit

Revolutionary Breakthrough in Gene Therapy! 

The NHS has approved the first gene-editing therapy using CRISPR technology to potentially cure beta thalassaemia, a severe blood disorder. This cutting-edge treatment reprograms patients' stem cells, eliminating the need for lifelong blood transfusions

At Broken String Biosciences, we’re excited to see how advancements in genome editing are transforming healthcare. This milestone underscores the immense potential of gene therapies to change lives.
#GeneTherapy #CRISPR 

Read more here: https://lnkd.in/eStW-nNr

INDUCE-seq® can identify DNA double strand breaks without the need for DNA amplification, thus greatly increasing sensitivity and signal to noise ratio. Watch our Chief Scientific Officer, Prof. Simon Reed speak to the sensitivity and specificity of INDUCE-seq and its additional capabilities here: 
https://lnkd.in/ed3dc35z


If you are looking for a highly sensitive assay for off-target detection in your gene-edited cell or gene therapy programs, simply contact us at partnerships@brokenstringbio.com.

Exciting News!  

We are thrilled to welcome Steve Becker as our Chief Commercial Officer. With over 30 years of experience in the global life sciences industry and a stellar track record, Steve will spearhead the commercialization of our pioneering DNA break-mapping platform, INDUCE-seq®. Steve's leadership will be pivotal as we enhance our offerings in the cell and gene therapy market, ensuring transformative treatments become a safe reality for patients worldwide. Welcome aboard, Steve! 🎉

Read more here: https://lnkd.in/ds3i__ac

 #CellAndGeneTherapy #GeneEditing #INDUCEseq

We’ve had an incredible time in Copenhagen, Baltimore, Vancouver and more recently, Rome. We're greatly encouraged by the widespread support of INDUCE-seq from industry partners, current and prospective clients, and regulatory groups. If you missed us at any of these meetings, view our scientific poster here: https://lnkd.in/eZQbQQSw 

If you'd also like to learn how you can use INDUCE-seq® for the unbiased detection of off-targets in your gene edited cell & gene therapy programs, email us at partnerships@brokenstringbio.com. 

#GeneEditing #CellandGeneTherapy

Still buzzing after attending last week's Federation of American Societies for Experimental Biology (FASEB) conference on Genome Engineering held in the beautiful city of Rome. 

The conference was a treasure trove of knowledge, featuring incredible advancements in genome engineering. We heard about the latest developments in base and prime editing, novel CRISPR systems, precise therapeutic editing, and exciting progress in delivery methods to humans. The discussions were intellectually stimulating, with a key focus on:

1) **Overcoming unintended double-strand breaks (DSBs)** in our editing systems and developing methods to detect and quantify these DSBs accurately (check out what we do at Broken String Biosciences to address this problem!).

2) **Streamlining the preclinical drug development path** from both experimental and regulatory perspectives. This is crucial to ensuring safety while shortening development timelines and reducing costs, ultimately providing treatments for rare diseases and neglected patient populations (it was humbling to finally meet Fyodor Urnov, who has long been at the forefront of this endeavor 💫).

3) **Improving access to novel therapies**, including addressing cost barriers and ensuring access to clinical trials and/or marketed therapies. One additional recurring theme was the bias around reference genomes and the need to better understand genomic variations in different geographic regions and populations, which could impact the efficacy and safety of cell and gene therapies.

What made this event truly special was the vibrant community of scientists who gathered to share their insights and foster collaborations. The social interactions and community building were as enriching as the scientific content (obviously we had to sample gelato while in Rome!). The backdrop of Rome added a unique charm, providing the perfect setting for networking and forming lasting connections - combined by flawless organisation by Faseb's Joanna U. Engstrom, DES and team AND the scientific organisers Shengdar Q. Tsai, Nicole M. Gaudelli, Philip Gregory, Angelo Lombardo! 👏 👏 

I'm grateful for the opportunity to be part of such a dynamic and forward-thinking community. Looking forward to applying these insights and continuing the conversation on advancing genome engineering! #FASEB2024 #GenomeEngineering #ScientificCommunity #CellandGeneTherapies

I'm seeking an experienced quality professional to join our team at Broken String Biosciences. We are a rapidly expanding organisation offering a foundational opportunity in shaping our QMS and quality culture in a dynamic organisation and industry. 

Recruiters: Please note that this post is exclusively for direct applicants. This role is not open for agency representation as it is exclusive with someone already. I value being connected with you but please don't contact me about this 😉. Thank you.

On a warm Sunday evening, David R. Liu kicked off an exceptionally exciting program for this year’s FASEB conference on Genome Engineering in the beautiful city of Rome 🇮🇹 
He presented his latest groundbreaking findings, called eePASSIGE—an improved version of PASSIGE (prime-editing-assisted site-specific integrase gene editing). This method, once the challenge of targeted and efficient delivery to humans is solved, could address a fundamental issue in the gene therapy field: how to insert a large piece of DNA into a specific genomic location.

In addition to David Liu's presentation, this meeting's agenda is packed with thrilling talks about novel advancements in genome engineering, ranging from base and prime editors to new CRISPR systems, precise therapeutic editing, and advancements in delivering these reagents to humans.

One major question being raised by both speakers and the audience alike is: How can we overcome unintended double-strand breaks (DSBs) in our editing systems, AND, if we cannot, how can we precisely and efficiently detect and quantify these wanted and unwanted DSBs? At Broken String Biosciences we have developed INDUCE-seq, a novel DSB assay that detects and quantifies DSBs in any cell type with unprecedented sensitivity. If you want to learn more, connect with me or send me a message!

Thank you to the Federation of American Societies for Experimental Biology (FASEB) for such a fantastic meeting! 

#GENESRC #FASEB #GenomeEditing #doublestrandbreaks #genomics #therapeuticediting #CRISPR

news impact assignment basic	general
public peers	general	Aug 23, 2024 7:41 PM	912cb98d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	a009f791
crunchbase profile	general
li profile	general	Aug 23, 2024 7:41 PM	59b295d7
translate crunchbase fundingrounds	general
peers	general	Aug 23, 2024 7:41 PM	65f99054
news basic	general	Aug 23, 2024 7:41 PM	7691437e
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BROK

COM:BROKENSTRINGBIO

Broken String Biosciences